

Cantwell And Paxton, Inc.

Patent, Trademark, and Copyright Services

2001 Jefferson Davis Hwy., Suite 1003

Arlington, VA 22202-3603

Phone: (703) 415-1616

Fax: (703) 415-1618 E-mail: cantpax@elinkisp.com

LG → RLS
NLS 03/22/02

Robert L. Sharp, Esq.

Tuesday, March 12, 2002

AMGEN INCORPORATED

M/S 27-4-A

One Amgen Center Drive

Thousand Oaks

CA 91320-1799

MyRef: 37111C

YourRef: S-225E

Re: U.S. Serial No. 08/182,183

Dear Mr. Sharp,

Pursuant to your letter request of March 8, 2002, we have hand-delivered to Examiner Robert Hayes, of Group 1600, the following: Hard Copy of a Draft Amendment faxed to the Examiner 3/8/02; Paper Copy of Revised Sequence Listing; A Computer Readable Format (Diskette) of Sequence Listing; Copies of Five Pieces of Correspondence Previously Sent to the PTO between 5/18/00 and 10/16/01 and An Associate Power of Attorney for the above-identified patent application.

Best regards,

CANTWELL & PAXTON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lin, et al.
Serial No.: 08/182,183
Filed: May 23, 1994
For: Glial Cell Line-Derived Neurotrophic Factor
Docket No.: S-225E

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

Respectfully submitted,



Robert L. Sharp
Attorney/Agent for Applicant(s)
Registration No.: 45,609
Phone: (805) 447-5992
Date: March 8, 2002

Please send all future correspondence to:

U.S. Patent Operations//RLS
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Per the Request
of Arlene, this
page was not
Filed.